Ki67 AND CD138/SYNDECAN-1 IMMUNOEXPRESSION IN AMELOBLASTOMAS

Abstract

Objective To assess Ki67 and CD138/Syndecan-1 immunoexpression and investigate possible predictors of disease-free survival in patients with ameloblastomas. Study Design This is a retrospective cohort study. The study population consisted of individuals diagnosed with conventional ameloblastoma. The clinical, imaging, histopathological, and immunohistochemical expression of Ki67 and CD138/syndecan-1 proteins were analyzed. Kaplan-Meier analysis was used to estimate disease-free survival rates. The log-rank test and Cox proportional hazards regression were used to identify predictors of disease-free survival. A statistical significance level of 5% was established. Results Thirty-one individuals diagnosed with ameloblastoma were included in this study. Tumors were more frequent in the 2nd and 3rd decades of life and in brown-skinned individuals (58.1%), with a male to female ratio of 1.5:1. Only the initial treatment modality was statistically associated with a better prognosis in univariate (p = 0.026) and multivariate (p = 0.021) analyses, with a Hazard Ratio of 22.14 (95%CI = 1.60-305.73), favoring radical treatment. Conclusion None of the analyzed clinical, imaging, histopathological, or immunohistochemical characteristics were associated with disease-free survival in ameloblastomas. However, cases that received radical surgical treatment had a lower risk of recurrence. To assess Ki67 and CD138/Syndecan-1 immunoexpression and investigate possible predictors of disease-free survival in patients with ameloblastomas. This is a retrospective cohort study. The study population consisted of individuals diagnosed with conventional ameloblastoma. The clinical, imaging, histopathological, and immunohistochemical expression of Ki67 and CD138/syndecan-1 proteins were analyzed. Kaplan-Meier analysis was used to estimate disease-free survival rates. The log-rank test and Cox proportional hazards regression were used to identify predictors of disease-free survival. A statistical significance level of 5% was established. Thirty-one individuals diagnosed with ameloblastoma were included in this study. Tumors were more frequent in the 2nd and 3rd decades of life and in brown-skinned individuals (58.1%), with a male to female ratio of 1.5:1. Only the initial treatment modality was statistically associated with a better prognosis in univariate (p = 0.026) and multivariate (p = 0.021) analyses, with a Hazard Ratio of 22.14 (95%CI = 1.60-305.73), favoring radical treatment. None of the analyzed clinical, imaging, histopathological, or immunohistochemical characteristics were associated with disease-free survival in ameloblastomas. However, cases that received radical surgical treatment had a lower risk of recurrence.